(Hypertension. 1996;27:426-432.)
© 1996 American Heart Association, Inc.
Articles |
Antihypertensive Properties of the Novel Calcium Antagonist Mibefradil (Ro 40-5967)
A New Generation of Calcium Antagonists?
Abstract Preclinical and initial clinical studies suggest that the novel calcium antagonist mibefradil has a unique combination of properties. Mibefradil was evaluated in a multicenter, double-blind, placebo-controlled, parallel group trial. After 4 weeks of a placebo run-in period, 202 eligible patients with mild to moderate hypertension were randomized to receive doses of 25, 50, 100, or 150 mg mibefradil or placebo once a day for 4 weeks. Blood pressure and heart rate were measured repeatedly at trough and peak (24 and 2 to 6 hours postdose, respectively) at the end of each period. Concentration-effect relationships were evaluated at trough on the last treatment day. A significant (P<.01 versus placebo) drop in blood pressure (diastolic and systolic) was observed at trough and peak in all mibefradil groups, with a trough-peak ratio greater than 0.8, high response rate, and a significant dose-response relationship (P<.001). The full antihypertensive effect of mibefradil was achieved within 1 to 2 weeks and was associated with a slight dose-dependent decrease in heart rate and increase in PQ time. Clear dissociation was observed between the effect on blood pressure and PQ time when concentration-effect relationships were evaluated. These results indicate that mibefradil is an effective and well-tolerated antihypertensive compound at doses of 25, 50, and 100 mg once daily. The incidence of treatment-related adverse events observed in the 25-, 50-, and 100-mg dose groups was lower than in the placebo group, but it was slightly higher in the 150-mg dose group, and three patients from this group were prematurely withdrawn because of an adverse event.
Key Words: antihypertensive agents • calcium antagonists • heart rate • mibefradil • hypertension, essential
This article has been cited by other articles:
 |
|
 |
|
  K. Hu, Y. Qu, Y. Yue, and M. Boutjdir Functional Basis of Sinus Bradycardia in Congenital Heart Block Circ. Res., March 5, 2004; 94 (4): e32 - e38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Bertolesi, C. Shi, L. Elbaum, C. Jollimore, G. Rozenberg, S. Barnes, and M. E. M. Kelly The Ca2+ Channel Antagonists Mibefradil and Pimozide Inhibit Cell Growth via Different Cytotoxic Mechanisms Mol. Pharmacol., August 1, 2002; 62(2): 210 - 219. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Glaser, M. Steinbach, C. Opitz, U. Wruck, and F. X. Kleber Torsades de pointes caused by Mibefradil Eur J Heart Fail, October 1, 2001; 3(5): 627 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G.-Q. Xiao, K. Hu, and M. Boutjdir Direct Inhibition of Expressed Cardiac L- and T-Type Calcium Channels by IgG From Mothers Whose Children Have Congenital Heart Block Circulation, March 20, 2001; 103(11): 1599 - 1604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Perchenet and O. Clément-Chomienne Characterization of Mibefradil Block of the Human Heart Delayed Rectifier hKv1.5 J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 771 - 778. [Abstract] [Full Text]
|
|
|
|
|
|
S. Wu, M. Zhang, P. A. Vest, A. Bhattacharjee, L. Liu, and M. Li A Mibefradil Metabolite Is a Potent Intracellular Blocker of L-Type Ca2+ Currents in Pancreatic beta -Cells J. Pharmacol. Exp. Ther., March 1, 2000; 292(3): 939 - 943. [Abstract] [Full Text]
|
|
|
|
 |
|
 H. Karam, J.-P. Clozel, P. Bruneval, M.-F. Gonzalez, and J. Menard Contrasting Effects of Selective T- and L-Type Calcium Channel Blockade on Glomerular Damage in DOCA Hypertensive Rats Hypertension, October 1, 1999; 34(4): 673 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nakamura, H. Ono, and E. D. Frohlich Differential Effects of T- and L-Type Calcium Antagonists on Glomerular Dynamics in Spontaneously Hypertensive Rats Hypertension, August 1, 1999; 34(2): 273 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Rossier, E. A. Ertel, M. B. Vallotton, and A. M. Capponi Inhibitory Action of Mibefradil on Calcium Signaling and Aldosterone Synthesis in Bovine Adrenal Glomerulosa Cells J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 824 - 831. [Abstract] [Full Text]
|
|
|
|
|
|
D. Tzivoni, H. Kadr, S. Braat, W. Rutsch, J. A. Ramires, and I. Kobrin Efficacy of Mibefradil Compared With Amlodipine in Suppressing Exercise-Induced and Daily Silent Ischemia : Results of a Multicenter, Placebo-Controlled Trial Circulation, October 21, 1997; 96(8): 2557 - 2564. [Abstract] [Full Text]
|
|
|
|
 |
|
 W. H. Frishman Mibefradil: A New Selective T-Channel Calcium Antagonist for Hypertension and Angina Pectoris Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1997; 2(4): 321 - 330. [Abstract] [PDF]
|
|